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The ability to target oncogenes in malignancies such as
CML, GIST, APML and ERBB2-positive breast cancer
has revolutionized the management of those diseases.
Interesting over 70% of melanomas contain genomic
amplification or mutations in one of the oncogenes
BRAF, NRAS, KIT, CCND1 or CDK4 that may induce
an oncogene addicted state. Inhibition of BRAF with
Vemurafenib or GSK2118436 in BRAF-mutant mela-
noma have shown responses in over 50% of patients
with advanced disease and in the case of Vemurafenib
striking improvements in survival compared to DTIC.
These data suggest that there are therapeutically targeta-
ble oncogenes in melanoma. However emergence of
resistance is common. A number of mechanisms of
resistance have been identified including reactivation of
the RAS/RAF/MEK/ERK pathway. Current focus is the
development of combination strategies including the
addition of MEK-inhibitors to BRAF-inhibitors and the
combining targeted agents with immunological agents
such as Ipilimumab. Together these data indicate that
targeting oncogenes in melanoma offers significant ther-
apeutic opportunities in one of the most challenging of
human malignancies for systemic therapy.
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